The two simultaneous Incyte trials in HS saw more than 40% of patients on povorcitinib achieving a clinical response.

The proceeds from the issue of shares will be used to accelerate the commercialisation of the Company's novel and innovative oral iron supplement, Iron Hydroxide Adipate Tartrate ("IHAT"), the ...

DUBLIN, IE / ACCESS Newswire / March 14, 2025 / Nemysis is pleased to announce signing of a Distribution and Supply Agreement (the “Agreement”) for its unique oral iron supplement, Iron Hydroxide ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

D printing of tubular biocomposites reveals moisture-sensitive actuators, offering insights into programmable materials for environmental responsiveness.